Pyramid Biosciences to Present at the 2022 Jefferies London Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--#PyramidBiosciences--Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, announced today that Chief Executive Officer, Brian Lestini, M.D., Ph.D., will present at the 2022 Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 2:40 PM GMT.

A live webcast of the presentation will be accessible on Pyramid’s website at Jefferies audiocast link or by visiting: https://wsw.com/webcast/jeff255/pyrb/1873179. A replay of the call will be archived for 90 days after the call.

For more information on the conference or to schedule a one-on-one meeting with the Pyramid Biosciences management, please contact your Jefferies representative.

About Pyramid Biosciences, Inc.
Founded in 2015, Pyramid Biosciences, Inc. is a Boston-based, clinical stage, biotechnology company dedicated to developing a portfolio of precision therapies targeting a wide range of molecularly defined diseases. Pyramid lead clinical program, PBI-200, is a novel, highly brain-penetrant, potential best-in-class TRK inhibitor for patients with NTRK-driven cancers. For more information, please visit www.pyramidbio.com.

Pyramid Biosciences Media Inquiries:
McDougall Communications on behalf of Pyramid Biosciences
Elizabeth Harness, senior consultant: elizabeth@mcdougallpr.com

Pyramid Biosciences Investor Inquiries:
Biren Amin, Pyramid Biosciences, CFO, and Chief Strategy Officer
bamin@pyramidbio.com